(Q39520295)

12 September 2017

title

A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages (English)

1 reference

Marga van de Vegte-Bolmer

12 September 2017

0 references

1 reference

0 references

1 reference

6

Marga van de Vegte-Bolmer

1 reference

12 September 2017

Susheel K Singh

3

0 references

Morten Hanefeld Dziegiel

Morten H Dziegiel

12

0 references

Teun Bousema

Teun Bousema

10

0 references

Michael Theisen

Michael Theisen

1

0 references

Robert Sauerwein

14

Robert Sauerwein

1 reference

12 September 2017

2

Will Roeffen

1 reference

12 September 2017

Gorm Andersen

4

1 reference

12 September 2017

Linda Amoah

5

1 reference

12 September 2017

Theo Arens

7

1 reference

12 September 2017

Régis Wendpayangde Tiendrebeogo

8

1 reference

12 September 2017

Sophie Jones

9

1 reference

12 September 2017

Bright Adu

11

1 reference

12 September 2017

Michael Christiansen

13

1 reference

12 September 2017

Theisen, M.

0 references

Roeffen, W.

0 references

Singh, S.K.

0 references

Andersen, G.

0 references

Amoah, L.

0 references

van de Vegte-Bolmer, M.

0 references

Arens, T.

0 references

Jones, S.

0 references

Bousema, T.

0 references

Adu, B.

0 references

Dziegiel, M.H.

0 references

Christiansen, M.

0 references

Sauerwein, R.

0 references

language of work or name

English

0 references

publication date

21 March 2014

1 reference

12 September 2017

2014

0 references

published in

Vaccine

1 reference

12 September 2017

0 references

32

1 reference

12 September 2017

issue

22

1 reference

12 September 2017

page(s)

2623-2630

1 reference

http://ugspace.ug.edu.gh/handle/123456789/25139

12 September 2017

exact match

0 references

cites work

A Research Agenda to Underpin Malaria Eradication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

A comparison of transmission-blocking activity with reactivity in a Plasmodium falciparum 48/45-kD molecule-specific competition enzyme-linked immunosorbent assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Transmission blocking malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Surface antigens of Plasmodium falciparum gametocytes--a new class of transmission-blocking vaccine targets?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

A longitudinal study of immune responses to Plasmodium falciparum sexual stage antigens in Tanzanian adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Transmission-blocking effects of sera from malaria-exposed individuals on Plasmodium falciparum isolates from gametocyte carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum in yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Production of non-glycosylated recombinant proteins in Nicotiana benthamiana plants by co-expressing bacterial PNGase F.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pfs48/45 in the green algae Chlamydomonas reinhardtii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Naturally acquired antibodies to the glutamate-rich protein are associated with protection against plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich pro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Flow cytometric readout based on Mitotracker Red CMXRos staining of live asexual blood stage malarial parasites reliably assesses antibody dependent cellular inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Lactococcus lactis-based vaccines from laboratory bench to human use: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Cultivation of fertile Plasmodium falciparum gametocytes in semi-automated systems. 1. Static cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Evidence of non-neutral polymorphism in Plasmodium falciparum gamete surface protein genes Pfs47 and Pfs48/45.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Plasmodium falciparum: production and characterization of rat monoclonal antibodies specific for the sexual-stage Pfs48/45 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Studies on antigenic competition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunogenicity of the Plasmodium falciparum glutamate-rich protein expressed by vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2014.03.020

1 reference

release_b5h7fe3dfzfbjapxuv4ahytghm

12 September 2017

Fatcat ID

0 references

1 reference